1. 4-year recurrence-free survival was significantly higher with nivolumab plus ipilimumab compared to placebo. 2. Overall survival was significantly higher ...
1. Objective response rate was not significantly different in patients treated with stereotactic body radiotherapy compared to those without. 2. ...
Click to read this study in the Journal of Clinical Oncology.
Click to read this study in The Lancet Oncology.
Click to read this study in the Journal of the American Academy of Dermatology.
Click to read this study in JAMA Dermatology.
Click to read this study in the Journal of the American Academy of Dermatology.
Click to read this study in JAMA Dermatology.
Click to read this study in JAMA Dermatology.
